Organon & Co.
No enriched coverage for $OGN in the last 7 days.
No SEC Form 4 filings for $OGN in the last 30 days.
See all $OGN insider activity →Organon Canada, a subsidiary of Organon & Co. (OGN), announced approval of NDUVRA 1% cream for atopic dermatitis in patients aged 2+. The steroid-free treatment was previously approved for plaque psoriasis. Atopic dermatitis affects up to 20% of children and 3% of adults globally. OGN shares closed at $13.73, up 0.07% on Friday.
Kelsey Norman, PharmD, discussed new data and guidelines reshaping hyperlipidemia management at the NEIAP 2026 Annual Forum. She highlighted the role of pharmacists in optimizing lipid-lowering therapies, including PCSK9 inhibitors, ezetimibe, and bempedoic acid. Norman noted the FDA's expanded indication for evolocumab (Repatha; Amgen) based on the VESALIUS-CV trial, and the missed primary endpoint in the Lp(a)HORIZON trial (NCT04023552) for pelacarsen (Novartis).
Organon (OGN) announced FDA acceptance of a supplemental New Drug Application for MIUDELLA, seeking to extend its use from 3 to 6 years. The FDA decision is expected in Q2 2027. MIUDELLA is currently approved for 3-year use and is anticipated to launch commercially in late 2026. Clinical trials showed 99% contraceptive effectiveness. Organon licensed MIUDELLA from Sebela Women's Health in June 2026.
Recent OGN coverage spans corporate actions, regulation and technology.
Positive regulatory approval expands Organon's dermatology pipeline and may boost sales.
No new product news; mention reinforces existing market position.
The FDA acceptance could lead to a longer‑duration product, expanding Organon's women's health portfolio and supporting the stock.
Minor dilution effect; modest impact on share supply.
The REMS enrollment rollout can affect near-term dispensing logistics and compliance costs, but it is not a new clinical or commercial outcome.
AlphAI scores every news story that mentions OGN with an AI model for sentiment and relevance, and aggregates insider trades from Organon & Co.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
Organon Canada, a subsidiary of Organon & Co. (OGN), announced approval of NDUVRA 1% cream for atopic dermatitis in patients aged 2+. The steroid-free treatment was previously approved for plaque psoriasis. Atopic dermatitis affects up to 20% of children and 3% of adults globally. OGN shares closed at $13.73, up 0.07% on Friday.
2 min readKelsey Norman, PharmD, discussed new data and guidelines reshaping hyperlipidemia management at the NEIAP 2026 Annual Forum. She highlighted the role of pharmacists in optimizing lipid-lowering therapies, including PCSK9 inhibitors, ezetimibe, and bempedoic acid. Norman noted the FDA's expanded indication for evolocumab (Repatha; Amgen) based on the VESALIUS-CV trial, and the missed primary endpoint in the Lp(a)HORIZON trial (NCT04023552) for pelacarsen (Novartis).
3 min readOrganon (OGN) announced FDA acceptance of a supplemental New Drug Application for MIUDELLA, seeking to extend its use from 3 to 6 years. The FDA decision is expected in Q2 2027. MIUDELLA is currently approved for 3-year use and is anticipated to launch commercially in late 2026. Clinical trials showed 99% contraceptive effectiveness. Organon licensed MIUDELLA from Sebela Women's Health in June 2026.
2 min readOrigin Enterprises plc transferred 15,349 treasury shares to satisfy share options under its Savings Related Share Option Scheme (UK). The number of treasury shares decreased from 12,050,357 to 12,035,008, with 107,706,523 ordinary shares in issue. The company is listed on Euronext Growth Dublin and the AIM market of the London Stock Exchange.
1 min readOrganon (NYSE: OGN) said its MIUDELLA copper IUD REMS program is open for enrollment via www.miudellarems.com. The REMS requires individual provider and separate healthcare setting certifications to support dispensing and insertion, aiming to reduce complications from improper insertion. MIUDELLA is indicated for up to three years of pregnancy prevention.
2 min readDrinane Juliana Papa (Head of Mfg & Supply) sold 14,761 shares of Organon & Co. (OGN) at $13.57 ($0.20M total) on 2026-08-05.
2 min readOrganon & Co. (OGN) filed an SEC Form 8-K — Submission of Matters to a Vote of Security Holders. 8-K false 0001821825 0001821825 2026-07-23 2026-07-23 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 23,
3 min readOTC Markets Group said Orogen Royalties Inc (TSX-V: OGN, OTCQX: OGNNF) qualified to trade on OTCQX Best Market, upgrading from OTCQB. It will trade on OTCQX under symbol OGNNF, with U.S. investors able to access disclosures and Level 2 quotes on OTCMarkets.com. Orogen focuses on precious and base metal royalties in North America.
4 min readOrganon & Co. (OGN) filed an SEC Form 8-K — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers. false 0001821825 0001821825 2026-06-09 2026-06-09 iso4217:USD xbrli:shares iso4217:USD xbrli:shares UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Repor
2 min readHanmi Pharmaceutical has announced a partnership with Organon to export three of its combination therapies for cardiovascular and respiratory conditions to Malaysia and the Philippines. This agreement strengthens Hanmi's presence in the rapidly growing Southeast Asian pharmaceutical market, with Organon handling marketing, distribution, and sales. Both companies aim to expand treatment options and improve access to medicines in the region.
2 min read
